VIVE Key Statistics, Chart & Performance
The current stock price of VIVE is 0.2201 USD. In the past month the price decreased by -51.09%. In the past year, price decreased by -78.42%.
VIVE Latest News, Press Relases and Analysis
VIVE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.83 | 224.14B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.61 | 203.30B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.43 | 150.59B | ||
| SYK | STRYKER CORP | 28.18 | 141.95B | ||
| IDXX | IDEXX LABORATORIES INC | 59.7 | 60.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.72 | 50.29B | ||
| RMD | RESMED INC | 25.84 | 37.34B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.43 | 36.44B | ||
| DXCM | DEXCOM INC | 34.12 | 24.89B | ||
| PODD | INSULET CORP | 71.6 | 23.02B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.05 | 19.33B |
Related stock screener links
About VIVE
Company Profile
Viveve Medical, Inc. engages in the design, development, manufacture, and marketing of platform medical technology. The company is headquartered in Englewood, Colorado and currently employs 47 full-time employees. The firm's CMRF technology is delivered through a radiofrequency (RF) generator, handpiece and treatment tip, that collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI), which is known as Viveve treatment. The Viveve System uses a method of delivering monopolar radiofrequency (RF) energy for treating tissue, such as Monopolar Radiofrequency Energy. The Viveve System also uses a cryogen surface cooling that enables volumetric heating of vaginal tissue. The Viveve System also uses a proprietary, controlled cryogen surface cooling that enables deep volumetric heating of vaginal tissue. The firm's subsidiary includes Viveve, Inc. and Viveve BV.
Company Info
VIVEVE MEDICAL INC
345 Inverness Dr S Bldg B Ste 250
Englewood COLORADO 80112 US
CEO: Scott Durbin
Employees: 47
Phone: 14085301900.0
VIVEVE MEDICAL INC / VIVE FAQ
What does VIVEVE MEDICAL INC do?
Viveve Medical, Inc. engages in the design, development, manufacture, and marketing of platform medical technology. The company is headquartered in Englewood, Colorado and currently employs 47 full-time employees. The firm's CMRF technology is delivered through a radiofrequency (RF) generator, handpiece and treatment tip, that collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI), which is known as Viveve treatment. The Viveve System uses a method of delivering monopolar radiofrequency (RF) energy for treating tissue, such as Monopolar Radiofrequency Energy. The Viveve System also uses a cryogen surface cooling that enables volumetric heating of vaginal tissue. The Viveve System also uses a proprietary, controlled cryogen surface cooling that enables deep volumetric heating of vaginal tissue. The firm's subsidiary includes Viveve, Inc. and Viveve BV.
What is the current price of VIVE stock?
The current stock price of VIVE is 0.2201 USD. The price decreased by -15.35% in the last trading session.
What is the dividend status of VIVEVE MEDICAL INC?
VIVE does not pay a dividend.
What is the ChartMill rating of VIVEVE MEDICAL INC stock?
VIVE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for VIVEVE MEDICAL INC?
VIVEVE MEDICAL INC (VIVE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
How many employees does VIVEVE MEDICAL INC have?
VIVEVE MEDICAL INC (VIVE) currently has 47 employees.
What is the ownership structure of VIVEVE MEDICAL INC (VIVE)?
You can find the ownership structure of VIVEVE MEDICAL INC (VIVE) on the Ownership tab.
VIVE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VIVE. When comparing the yearly performance of all stocks, VIVE is a bad performer in the overall market: 98.42% of all stocks are doing better.
VIVE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VIVE. Both the profitability and financial health of VIVE have multiple concerns.
VIVE Financial Highlights
Over the last trailing twelve months VIVE reported a non-GAAP Earnings per Share(EPS) of -2.65. The EPS increased by 32.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
VIVE Forecast & Estimates
8 analysts have analysed VIVE and the average price target is 4.77 USD. This implies a price increase of 2066.52% is expected in the next year compared to the current price of 0.2201.
For the next year, analysts expect an EPS growth of 7.44% and a revenue growth 7.41% for VIVE